Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. The U.S. Food and Drug Administration (FDA) has agreed to Amicus' proposal for the Phase 1 study and subsequently converted the clinical hold of AT2220 to a partial hold to allow the conduct of this study.

In June 2008, the Company announced the commencement of a Phase 2 clinical trial of AT2220 in adults with Pompe disease based on data from both preclinical and Phase 1 studies. In February 2009, the Company announced it had suspended enrollment after two patients enrolled in the trial experienced serious adverse events that were probably related to treatment with AT2220. The AT2220 Investigational New Drug application (IND) was subsequently placed on clinical hold by the FDA.

The Company has completed a thorough evaluation of all data from these two subjects and has completed additional preclinical studies of AT2220. Based on these data, the Company proposed the planned Phase 1 study to FDA in order to further evaluate the pharmacokinetics of AT2220 in muscle, the key target tissue in Pompe disease. This study will be an open label, single dose study and will commence in the fourth quarter of this year. The Company expects data from this trial to be available in the first quarter of 2010. Based on the results of this study, the Company will determine the appropriate next steps for the program working in close collaboration with the FDA.

One of the recently completed preclinical studies evaluated the effects of various doses and regimen
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 PMG Research, Inc. announced ... is a network of sites that provide clinical research services ... million patient lives through its partnerships with large physician practices ... hub site locations in the Southeastern United States and spans ... the board will be held by: Dr. Robert ...
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
(Date:11/26/2014)... November 25, 2014 Continuing its award-winning ... earned three prestigious MarCom Awards for outstanding creative achievement ... a Platinum MarCom Award, the organization’s top honor, in ... St. Louis held in April of this year. The ... 14,000 attendees. Additionally, Nerium was awarded a Gold MarCom ...
(Date:11/26/2014)... Global biostimulants market is expected to ... estimated CAGR of 12.5%. In order to cater ... least ecological impacts, farmers are looking to adopt ... yield more effectively & efficiently. Biostimulants are consequently ... return on investments. , Leading companies in the ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4
... the work of the National Nanotechnology Initiative has just ... Technology (NSET) Subcommittee of the National Science and Technology ... Nanotechnology Coordination Office (NNCO). The 2007 NNI ... the NNI to ensure that the United States derives ...
... ... President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: PARS ) ... Board Changes, Robert F. Johnston has been elected to the ... Ben Dor have retired from,the Board., The Pharmos Board now consists ...
... and Commercial Adoption of the ... Axxent(R) Electronic Brachytherapy System, FREMONT, Calif., Jan. ... System, a proprietary cancer treatment,platform that utilizes X-rays to ... announced that it will,present at the 26th Annual JPMorgan ...
Cached Biology Technology:National Nanotechnology Initiative releases new strategic plan 2National Nanotechnology Initiative releases new strategic plan 3Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3Xoft to Present at the 26th Annual JPMorgan Healthcare Conference 2
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Cancer and its therapies, including chemotherapy and radiotherapy, ... possibly leading to patient malnutrition, and in severe cases, ... Forest University Comprehensive Cancer Center compilation of various existing ... Journal of Supportive Oncology . One ...
... Swedish medical university Karolinska Institutet (KI) have constructed a mathematical ... increase the understanding of the capacity of the working memory ... interact. One of the findings they have made with this ... that restricts the number of items we can normally store ...
... new study published as the cover article for the April ... ) promises to give physicians new ways to reduce deadly ... cord. In the report, scientists from Columbia University, NY, detail ... cells, called astrocytes, use to handle invading viruses and to ...
Cached Biology News:Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study 2Taste, odor intervention improves cancer therapy, according to Virginia Tech, Wake Forest study 3Computer simulations explain the limitations of working memory 2West Nile virus studies show how star-shaped brain cells cope with infection 2
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... greater than 1500 known aptamer sequences. Add ...
... provides a comprehensive epitope analysis service ... on Paraflo microfluidic chips for immunological ... This comprehensive service includes assistance with ... sample(s) provided by you, single or ...
... Parkers MX80 family of positioners, offering longer travel ... patterns mimic the MX80 family, allowing users to ... to build multi-axis systems., , Miniature linear ... Accelerations to 5 gs , Velocities to 3 ...
... step in the evolution of laboratory automation. ... delivers labware to multiple laboratory instruments, LabLinx ... throughput of ordinary microplate robots. It allows ... configurations to meet any labs specific automation ...
Biology Products: